Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis
Fortress Biotech, Inc. (FBIO)
Last fortress biotech, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
fortressbiotech.com
Company Research
Source: GlobeNewswire
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today announced that the final analysis of data and additional global longitudinal strain response from the Phase 1a/1b trial of Caelum’s CAEL-101 (mAb 11-1F4) for the treatment of relapsed or refractory amyloid light chain (“AL”) amyloidosis will be presented in an oral session at the 16th International Symposium on Amyloidosis, to be held March 26-29, 2018, in Kumamoto, Japan. The Phase 1a/1b trial was conducted at Columbia University. Details of the presentation are as follows: Title: Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody 11-1F4 (CAEL-101) in Patients with AL AmyloidosisSession: AL amyloidosis 3Oral Presentation Number: 39Date and Time: Tuesday, March 27, 2018, at 4:30 p.m. JSTLocation: KKR Hotel KumamotoPresenter: Camille V. Edwards, M.D., Boston Me
Show less
Read more
Impact Snapshot
Event Time:
FBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBIO alerts
High impacting Fortress Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
FBIO
News
- Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Fortress Biotech, Inc. (NASDAQ: FBIO) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Fortress Biotech to Participate in 36th Annual ROTH Conference [Yahoo! Finance]Yahoo! Finance
FBIO
Earnings
- 11/14/23 - Beat
FBIO
Sec Filings
- 2/14/24 - Form SC
- 1/26/24 - Form 8-K
- 1/9/24 - Form 4
- FBIO's page on the SEC website